Gyre Therapeutics Q2 revenue down 14% to $25.2M, net income up to $4.5M; receives NMPA approval for avatrombopag

GYRE THERAPEUTICS, INC.

2024-Q2 EPS reported $0.04 revenue$52,397,000

Q2 revenue $25.2M (-14% YoY) on normalized ETUARY sales; net income $4.5M vs $3.8M YoY.
H1 revenue $52.4M (-3.5% YoY); net income $14.5M vs $8.0M YoY, driven by lower costs.
Received NMPA approval for avatrombopag for CLD thrombocytopenia (July 2024); expanded rare disease portfolio.
IND approved for F230 in PAH; Phase 3 F351 CHB data expected early 2025; U.S. IND for F351 in MASH by end 2024.
Appointed David M. Epstein to Board; cash and investments ~$54M, sufficient for 12+ months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.